Community-acquired pneumonia and skin infections: does ceftaroline improve outcomes?
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Results suggest ceftaroline is a safe and effective therapeutic alternative for patients with community-acquired pneumonia (CAP) or complicated skin and skin structure infections (cSSSI), but it should currently be reserved as an alternative rather than first-line option.
Why this matters
Early, widespread use of ceftaroline may promote resistance, and current evidence calls for more conservative conclusions regarding its place in therapy.
Systematic review and meta-analysis comparing efficacy and safety of ceftaroline vs standard antibiotic regimens for CAP and cSSSIs.
3 randomized controlled trials per indication.
Comparator agents: Ceftriaxone in CAP and vancomycin plus aztreonam in cSSSI.